Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
taranabant · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| taranabant | DRUG | - |
Inclusion Criteria: * Obese patients with a body mass index between 30kg/m2 and 43 kg/m2, inclusive (BMI between 27 kg/m2 and 43kg/m2, inclusive for those with obesity-related comorbidities including hypertension, dyslipidemia and sleep apnea). Exclusion Criteria: * Patients with serious or unsta...
Taranabant is an investigational small molecule being studied for smoking cessation and for obesity and obesity-related medical conditions. It is in Phase 2 clinical development by Merck & Company, Inc. (MRK).
Taranabant is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The drug is currently in Phase 2 clinical trials for smoking and obesity-related conditions.
Taranabant is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two Phase 2 trials have been completed, one in smoking and one in obesity.
Taranabant has been studied in two completed Phase 2 trials. NCT00109135 investigated the drug as an aid for smoking cessation in 300 chronic cigarette smokers. NCT00131430 was an 18-month efficacy and safety study in 500 obese patients with obesity-related medical conditions.
Taranabant is a distinct investigational compound developed by Merck. It is not known by any other names in the clinical trial data. It is being studied separately for smoking cessation and for obesity.